Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02291016 · ClinicalTrials.gov registry record · NA
COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers
A NA study of COPD Exacerbation, sponsored by University of Tennessee Graduate School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT02291016 is a NA study of COPD Exacerbation that has completed, run by University of Tennessee Graduate School of Medicine. The registered enrollment target is 7 participants, below the 46-participant average among 3 other COPD Exacerbation trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02291016, a NA study of COPD Exacerbation, has completed, sponsored by University of Tennessee Graduate School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare drug delivery and lung function after treatment with formoterol from a nebulizer versus a dry powder inhaler (DPI) in patients recovering from severe exacerbations of COPD. This is to determine if one device is superior in providing better lung function and drug deposition in this clinical setting.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Formoterol
Study Locations (1)
Tennessee
- University of Tennessee Medical Center - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02291016
The ClinicalTrials.gov registry entry for NCT02291016 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 46-participant average among 3 other COPD Exacerbation trials with a reported enrollment target (85% lower). The listed sponsor is University of Tennessee Graduate School of Medicine, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COPD Exacerbation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02291016 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT02291016 about?
NCT02291016 is a clinical study titled "COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers". The purpose of this study is to compare drug delivery and lung function after treatment with formoterol from a nebulizer versus a dry powder inhaler (DPI) in patients recovering from severe exacerbations of COPD. This is to determine if one device is superior in providing better lung function and dr...
What is the current status of trial NCT02291016?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2015-02. Estimated completion is 2016-03.
What conditions does trial NCT02291016 study?
This clinical trial studies the following conditions: COPD Exacerbation.
What interventions are being tested in trial NCT02291016?
The interventions under investigation include: Placebo (OTHER), Formoterol (DRUG).
Who is sponsoring clinical trial NCT02291016?
This trial is sponsored by University of Tennessee Graduate School of Medicine, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02291016 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD Exacerbation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.